LL-37 (Cathelicidin)

LL-37 operates through a mechanistic repertoire that is substantially more complex than any single-target therapeutic. Its biological effects span the physical destruction of pathogen membranes, the orchestration of immune cell recruitment and activation, the promotion of tissue repair through angiogenesis, and — in a biological paradox — both pro- and anti-tumor signaling depending on tissue context. This multifunctionality reflects LL-37’s evolutionary design as a host defense peptide (HDP) rather than a narrowly targeted drug: it was optimized by natural selection for broad situational utility, not pharmacological precision.

Antimicrobial Membrane Disruption

The primary antimicrobial mechanism is direct biophysical membrane disruption, driven by LL-37’s cationic charge and amphipathic alpha-helical structure:

• LL-37 carries a net positive charge that electrostatically attracts it to the anionic outer leaflets of bacterial membranes (lipopolysaccharide in Gram-negatives; teichoic acid in Gram-positives), selectively targeting prokaryotic membranes over the neutral zwitterionic outer leaflets of mammalian cells
• Upon membrane contact, LL-37 undergoes conformational transition from a disordered state in aqueous solution to a structured amphipathic alpha-helix — concentrating on the membrane surface and inserting its hydrophobic face into the lipid bilayer core
• Membrane permeabilization models include the “carpet model” (peptide covers the membrane surface until threshold disruption), the “toroidal pore model” (peptide-lipid pores that span the bilayer), and direct lipid displacement — the specific mode varies by bacterial species and LL-37 concentration
• LL-37 is effective against both biofilm and planktonic bacteria, targeting the extracellular polymeric substance (EPS) matrix of biofilms directly — a capability most conventional antibiotics lack
• At concentrations above the minimum inhibitory concentration (MIC), LL-37 demonstrates remarkable intracellular killing ability, outperforming conventional antibiotics including cefazolin and clindamycin against S. aureus in controlled assays

Immunomodulation — Innate and Adaptive Immune Regulation

Beyond direct killing, LL-37 functions as a cytokine-independent immune orchestrator across multiple cellular pathways:

• Chemotaxis: LL-37 induces FPRL1 (formyl peptide receptor-like 1)-mediated recruitment of neutrophils, monocytes, and mast cells to sites of infection or injury — functioning as a molecular beacon that accelerates immune cell mobilization
• Cytokine modulation: LL-37 upregulates IL-8 production and enhances expression of CXCR4, CCR2, and IL-8RB on immune cells; simultaneously, it neutralizes lipopolysaccharide (LPS)-mediated macrophage activation, functioning as both a pro-inflammatory alarm signal and an anti-inflammatory brake depending on context
• Adaptive immune bridge: LL-37 promotes dendritic cell maturation and antigen presentation, connecting innate pathogen recognition to adaptive T-cell responses — a function that positions it as more than a simple antimicrobial and more akin to a regulatory immunological signal
• Vitamin D axis integration: The expression of LL-37 is directly upregulated by 1,25-(OH)₂D₃ (active vitamin D) in macrophages — the mechanistic basis for the well-documented link between vitamin D deficiency and susceptibility to mycobacterial infections including tuberculosis
• Critically, LL-37 can exhibit pro-inflammatory or anti-inflammatory phenotypes depending on the cell type, local concentration, and inflammatory context — a dual behavior that makes therapeutic dosing nuanced and that underlies some of its adverse effect concerns

Wound Healing and Tissue Regeneration

LL-37 plays a non-redundant role in tissue repair — a function clinically evidenced by its deficiency in chronic wound epithelium:

• LL-37 is absent or significantly depleted in chronic non-healing ulcers compared to healthy skin, establishing a physiological deficit that has motivated exogenous therapeutic applications
• It stimulates angiogenesis (blood vessel formation) by promoting endothelial cell proliferation, migration, and tubule-like structure formation — the vascular scaffolding required for effective wound granulation tissue formation
• LL-37 drives re-epithelialization by promoting keratinocyte migration and differentiation, directly accelerating the surface closure phase of wound repair
• LPS neutralization at wound sites prevents bacterial toxin-driven inflammatory escalation that impedes healing — a dual antimicrobial/anti-inflammatory benefit specifically advantageous in polymicrobially infected chronic wounds
• The topical application of LL-37 in dexamethasone-treated mouse models demonstrated significantly increased vascularization and re-epithelialization relative to untreated controls — the preclinical foundation for wound care clinical trials

Cancer Biology — A Complex, Context-Dependent Role

LL-37 occupies a uniquely ambiguous position in oncology, demonstrating both tumor-suppressive and tumor-promoting effects depending on cancer type:

• Tumor-suppressive: In colon cancer, glioblastoma, hematologic malignancy, gastric cancer, and oral squamous cell carcinoma, LL-37 suppresses proliferation and induces apoptosis via a GPCR-p53-Bax/Bak/Bcl-2-AIF/EndoG cascade — a caspase-independent pathway that directly activates programmed cell death
• Tumor-promoting: In breast, ovarian, and lung cancers, LL-37 has been demonstrated to promote tumor cell growth, invasion, and angiogenesis — and tumor-derived LL-37 in the tumor microenvironment polarizes macrophages toward the immunosuppressive M2 phenotype
• This dichotomy is mechanistically driven by differential receptor expression across cancer types — the same FPRL1 receptor that mediates immune cell recruitment in healthy tissue can promote mitogenic signaling in certain tumor cell lineages
• The FDA has explicitly flagged this protumorigenic potential in certain tissue contexts as a core safety concern justifying its current unapproved compounding status

LL-37’s research evidence base is qualitatively different from conventional pharmaceutical development pipelines. As an endogenous human peptide, it has accumulated decades of mechanistic, in vitro, animal model, and translational research — with the literature spanning antimicrobial pharmacology, immunology, dermatology, wound care, and oncology. However, its clinical trial evidence base is substantially thinner than its preclinical profile — a common characteristic of endogenous peptides that face formulation, delivery, stability, and dosing challenges in therapeutic development.

Structural and Mechanistic Research

• Nuclear magnetic resonance (NMR) and synchrotron X-ray scattering studies have characterized LL-37’s interaction with lipid bilayers, confirming its alpha-helical membrane-inserting structure and validating the biophysical basis of its antimicrobial activity at the molecular level
• A landmark 2025 Nature Scientific Reports study characterized the biophysical and transcriptomic profile of novel LL-37-derived analogues, demonstrating that structure-activity optimization can produce derivatives with lower MICs and faster bactericidal kinetics than the parent peptide against MDR E. coli and ESKAPE pathogens — establishing the next-generation AMP development rationale
• Structural work has confirmed LL-37’s resistance to proteolytic degradation in solution relative to most other peptides — an intrinsic property that reduces but does not eliminate formulation instability challenges

In Vitro Antimicrobial Evidence

• LL-37 has been demonstrated effective against >38 bacterial species, spanning Gram-positive (S. aureus, including MRSA; S. pneumoniae; Enterococcus), Gram-negative (E. coli; P. aeruginosa; K. pneumoniae; A. baumannii), and intracellular pathogens (M. tuberculosis)
• Antiviral activity has been demonstrated against influenza A, respiratory syncytial virus (RSV), HIV-1, herpes simplex viruses (HSV-1, HSV-2), and SARS-CoV-2 — through envelope membrane disruption and direct viral particle inactivation mechanisms
• Antifungal activity spans Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus — pathogens of critical clinical importance in immunocompromised patients
• Biofilm disruption against P. aeruginosa and S. aureus has been consistently demonstrated across multiple independent laboratory models — addressing one of the most clinically intractable resistance mechanisms
• Importantly, LL-37 demonstrates synergistic activity with conventional antibiotics, producing combination effects greater than either agent alone — suggesting a role as adjunct therapy rather than monotherapy replacement

Preclinical In Vivo Evidence

Wound healing models: Topical LL-37 application in dexamethasone-immunosuppressed mice demonstrated significantly accelerated vascularization and re-epithelialization — establishing proof-of-concept for wound care applications in immunocompromised hosts.

Antimicrobial animal models: LL-37 reduced bacterial burden in murine models of P. aeruginosa lung infection, S. aureus wound infection, and systemic endotoxemia — confirming in vivo pharmacodynamic activity consistent with its in vitro profile.

Alzheimer’s disease caution: A 2022 Molecular Psychiatry study in mouse and primate models demonstrated that LL-37 promoted CLIC1 membrane translocation, driving microglial hyperactivation, neuroinflammation, elevated amyloid-β, increased neurofibrillary tangles, and cognitive impairment — raising an important neurotoxicity concern for systemic long-term LL-37 elevation or administration.

Male reproductive toxicity: FDA has cited nonclinical research findings suggesting detrimental effects on male reproduction as a specific safety concern that currently prevents its classification as suitable for compounding.

Clinical Trial Evidence

Phase 1 Melanoma Trial (NCT02225366): A completed Phase 1 trial of intratumoral injection of LL-37 in melanoma patients with cutaneous metastases demonstrated significant potency against cancer cells — the first and, as of May 2026, most advanced human oncology clinical trial for LL-37.

• Results confirmed intratumoral anti-tumor activity consistent with preclinical mechanistic predictions
• Tolerability at intratumoral doses was acceptable, supporting Phase 2 planning
• Systemic safety data from this route were limited by the localized delivery approach

Wound care clinical evaluation: LL-37 has been evaluated in early-phase clinical settings as a topical treatment for polymicrobially infected chronic wounds, as referenced in the Guide to Pharmacology database. Formal published Phase 2 RCT data for this indication are not yet available in the peer-reviewed literature as of May 2026.

Extracellular vesicle delivery system (2025): A Nature Scientific Reports study (2025) demonstrated that LL-37 loaded into epithelial cell-derived extracellular vesicles (EpEVs-LL37) produced dose-dependent, statistically significant wound healing enhancement at 18 hours post-treatment in cell models — representing the frontier of delivery system innovation for LL-37 clinical translation.

Clinical and Regulatory Development

LL-37 occupies a unique regulatory position as an endogenous human peptide with extensive preclinical evidence but limited formal clinical development:

• As of May 2026, LL-37 has no FDA approval for any therapeutic indication and is not the subject of any active NDA or BLA submission
• It is not listed on the FDA’s 503A Category 1 or Category 2 bulk compounding substance lists, and no formal positive compounding eligibility determination has been made
• The FDA has specifically cited insufficient safety information, potential immunogenicity by certain routes of administration, peptide-related impurity concerns, protumorigenic potential in certain tissues, and nonclinical evidence of male reproductive toxicity as the primary bases for its current unapproved compounding status
• In April 2026, the FDA announced plans to remove LL-37 from its Category 2 list — not to approve it, but to initiate a formal PCAB (Pharmacy Compounding Advisory Committee) safety review, tentatively scheduled for early 2027
• This represents a meaningful regulatory development: PCAB review could ultimately lead to compounding eligibility if safety concerns are adequately characterized, but it confers no current legal authorization for compounding

Regulatory Status

FDA (United States): LL-37 (Cathelicidin) is not approved for any human therapeutic use. It is not on any 503A/503B positive compounding list. The FDA has explicitly stated it lacks sufficient safety information to determine whether compounded LL-37 would harm humans, and has flagged specific preclinical safety signals including protumorigenic potential and male reproductive toxicity. Selling or administering compounded LL-37 outside of an approved clinical trial constitutes marketing of an unapproved drug under 21 U.S.C. § 331.

PCAB Advisory Committee Review: The FDA has announced a PCAB committee meeting — tentatively before the end of February 2027 — to formally evaluate cathelicidin LL-37 for potential future compounding category determination. This process does not confer approval or compounding eligibility pending the committee’s determination.

International: No regulatory authority — EMA, Health Canada, TGA, or otherwise — has approved LL-37 for any therapeutic indication as of May 2026. Its availability outside clinical trial settings is limited to research-grade peptide vendors, whose products carry no manufacturing quality guarantees.

LL-37’s safety profile is fundamentally different from conventional drug safety profiles because it is an endogenous human peptide with known physiological roles — meaning the body produces it naturally — but exogenous administration at therapeutic doses introduces risks that endogenous levels do not. The key safety considerations span direct cytotoxicity, immunological unpredictability, oncological risk heterogeneity, reproductive toxicity, and neurological risk from chronic systemic elevation.

Established Biological Safety Properties

• Endogenous tolerance: At physiological concentrations, LL-37 is well-tolerated and essential — its complete absence produces immunodeficiency and impaired wound healing, as observed in patients with morbus Kostmann (genetic LL-37 deficiency)
• Cytotoxicity to normal cells: At supraphysiological concentrations, LL-37 is cytotoxic to normal eukaryotic cells as well as pathogens — the concentration window between antimicrobial efficacy and mammalian cell toxicity is the primary formulation and dosing challenge
• Hemolytic activity: At higher doses, LL-37 demonstrates hemolytic activity against red blood cells — a dose-limiting toxicity concern for systemic injectable formulations that does not apply to topical use
• Injection site reactions and immunogenicity: The FDA has specifically cited immunogenicity risk by certain routes of administration and complexities with peptide-related impurities as safety barriers to compounding eligibility

Serious Safety Signals Under FDA Review

The FDA’s April 2026 formal safety statement identified several critical concerns:

• Protumorigenic potential: Nonclinical research demonstrates that LL-37 promotes tumor growth, invasion, and angiogenesis in breast, ovarian, and lung cancer contexts; M2 macrophage polarization in the tumor microenvironment may suppress anti-tumor immunity
• Male reproductive toxicity: Nonclinical findings suggest detrimental effects on male reproductive function — a safety signal that has not been characterized in human clinical trials and that the FDA explicitly cites as insufficient-to-evaluate
• Neurological risk: A 2022 Molecular Psychiatry primate and mouse study demonstrated LL-37 promoted Alzheimer’s disease–like pathology — elevated amyloid-β, neurofibrillary tangles, neuronal death, brain atrophy, and cognitive impairment — via CLIC1 activation
• Dual immune regulation: LL-37’s simultaneous pro- and anti-inflammatory signaling capacity means that exogenous administration could paradoxically worsen autoimmune conditions, inflammatory diseases, or cytokine storm syndromes in susceptible individuals
• Insufficient nonclinical toxicology data: The FDA’s explicit position is that it lacks sufficient safety-related information to know whether compounded LL-37 causes harm in humans — a formal acknowledgment of the evidence gap that distinguishes this peptide from those with complete nonclinical dossiers

Manufacturing Quality in the Unregulated Market

For LL-37 sourced outside of clinical trials through research chemical vendors:

• No cGMP manufacturing standards apply; contamination with endotoxins, residual TFA, heavy metals, and microbial load represent serious risks for any injectable preparation
• LL-37’s amphipathic structure makes it particularly susceptible to aggregation and adsorption losses during handling, meaning vendor-supplied products may have substantially different potency than labeled
• Peptide-related impurities — including truncated sequences, oxidized methionines, and racemized residues — are characteristic challenges of unregulated LL-37 synthesis and are specifically cited by the FDA as a manufacturing safety concern

No pharmacovigilance mechanism exists to capture adverse events from non-trial use; protumorigenic and reproductive risks in particular would likely manifest only after prolonged, repeated dosing

1. Kościuczuk EM, et al. (2021). The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. PMC / Frontiers in Microbiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC8227053/
2. Mookherjee N, et al. (2020). Significance of LL-37 on Immunomodulation and Disease Outcome. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC7246396/
3. Zhong F, et al. (2025). Decoding LL-37: Structure and antimicrobial mechanisms. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S156713482500142X
4. Fabisiak A, et al. (2016). LL-37, the only human member of the cathelicidin family. BBRC, 473(4). https://www.sciencedirect.com/science/article/pii/S000527360600126X
5. Nibbering PH, et al. (2012). Cationic Antimicrobial Peptide LL-37 Is Effective against both Extra- and Intracellular Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 57(3). https://journals.asm.org/doi/10.1128/aac.01650-12
6. Felício MRS, et al. (2017). Advances in delivery systems for the therapeutic application of LL-37. Journal of Drug Delivery Science and Technology. https://www.sciencedirect.com/science/article/abs/pii/S1773224720313058
7. Santos EM, et al. (2011). Wound healing activity of LL-37. Peptides, 32(7). https://pubmed.ncbi.nlm.nih.gov/21693141/
8. Jiang C, et al. (2022). Host Immune Defense Peptide LL-37 Activates Caspase-Independent Apoptosis and Suppression of Colon Cancer. Cancer Research, 72(24), 6512–6523. https://aacrjournals.org/cancerres/article/72/24/6512/576212/
9. Chen X, et al. (2022). Human antimicrobial peptide LL-37 contributes to Alzheimer’s disease progression. Molecular Psychiatry, 27, 4790–4799. https://www.nature.com/articles/s41380-022-01790-6
10. Bao Y, et al. (2022). Repurposing human antibacterial peptide LL-37 for cancer treatment. Frontiers in Pharmacology, 13, 944147. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.944147/full
11. FDA. (2026, April). Certain Bulk Drug Substances for Use in Compounding — Cathelicidin LL-37 Safety Statement. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
12. RAPS. (2026, April). FDA Considers Adding a Dozen Peptides to its Bulk Drug Compounding List. https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html
13. Wikipedia. Cathelicidin antimicrobial peptide. https://en.wikipedia.org/wiki/Cathelicidin_antimicrobial_peptide
14. Nature Scientific Reports. (2025). Cathelicidin LL37-loaded extracellular vesicles from epithelial cells in wound healing. https://www.nature.com/articles/s41598-025-28377-9
15. Nature Scientific Reports. (2025). Biophysical and transcriptomic characterization of LL-37 derived AMP. https://www.nature.com/articles/s41598-025-22890-7